Benefit of Micropulse Transscleral Cyclophotocoagulation in
MP-TSCPC in a 120-s setting reduces IOP with a 6-month success of 45.5%. Only late (more than 6 month) failure seems to present a benefit for retreatment.

A Study was conducted to assess the micropulse transscleral cyclophotocoagulation (MP-TSCPC) efficacy, safety, factors of success and re-treatment benefit in open angle glaucoma (OAG).

Included were OAG patients naive to a cycloablative technique and subject to MP-TSCPC for 120 s at 2000 mW. The success was characterized as intraocular (IOP) pressure greater than 5 and less than 21 mmHg with IOP reduction more than 20% of baseline, better than negative light perception without any retreatments and visual acuity. The retreatment of MP-TSCPC was early and late, respectively before and after 6 months following operation.

--94 eyes in 94 patients (mean [SD] age 67.2 [13.4] years; 47.9% women) were included. The mean preoperative IOP was 24.9 mmHg and was reduced to 18.9 at month 6.

--The success rate decreased progressively over time and reached 45.5% at 6 months.

--Patients with 6-month surgical success had lower mean axial length than others (24.1 vs 25.5 mm).

--In patients with early and late MP-TSCPC re-treatment, the 6-month success rate was 16.7% and 63.6%, respectively.

Conclusively, MP-TSCPC performed in a 120-s setting reduced IOP, with 45.5% success at month 6 and few complications. Axial length was newly described as affecting success, probably linked to ciliary-body position. A re-treatment seemed to be of little benefit in non-responders or those with early failure.